We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




CD Diagnostics Acquires CLIA-Accredited Citrano Medical Laboratories

By LabMedica International staff writers
Posted on 30 Oct 2012
CD Diagnostics, Inc. More...
(Wynnewood, PA, USA) completed the purchase of 80% of the outstanding capital stock of Citrano Medical Laboratories, Inc. (CML; Towson, MD, USA).

CML provides clinical laboratory testing to physicians, clinics, and long-term care facilities. The combination of Citrano with CD Diagnostics creates an entity with both a strong R and D team that can produce Laboratory Developed Tests (LDTs), and a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostics laboratory dedicated to customer service in which these tests can be run.

CD Diagnostics' immunoassays use a small sample of a patient’s joint fluid (synovial fluid) to measure the presence of proteins or biomarkers that are produced by the body and are specific to a particular joint disease. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. Results are accurate and available within five to ten minutes. The first test, an immunoassay to diagnose infection in joint replacements, is planned for release in November 2012. Joint infection is a very serious condition that must be ruled out with any joint disease.

The first test, CD Diagnostics’ new synovial fluid assays will enhance Citrano’s portfolio of testing services, which currently include hematology, urinalysis, and a broad range of other services.

The acquisition of Citrano is one of the milestones achieved by CD Diagnostics since its incorporation in December 2011. In June 2012, the company signed a commercialization agreement with an orthopedic company for the development of its infection test, receiving USD 2.9 million in milestone payments.

Richard Birkmeyer, CEO of CD Diagnostics, commented, “When you have inflammation in a joint, it can be a wide range of causes such as Lyme disease, gout, bacterial infection. Our test tells exactly what is causing that pain, no matter what the joint.” Tests for other joint diseases are in development.

Related Links:

CD Diagnostics, Inc.
Citrano Medical Laboratories, Inc.



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
Latex Test
SLE-Latex Test
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New biomarkers could someday make it easy to spot Parkinson’s disease in a patient’s blood sample (Photo courtesy of Shutterstock)

Unique Blood-Based Genetic Signature Can Diagnose Parkinson’s Disease

Parkinson's disease is primarily recognized for its impact on the central nervous system. Recent scientific progress has shifted focus to understanding the involvement of the immune system in the onset... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The new tool is designed for accurate detection of structural variations in clinical samples (Photo courtesy of Karen Arnott/EMBL-EBI and Isabel Romero Calvo/EMBL)

ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data

Long-read sequencing technologies are designed to analyze long, continuous stretches of DNA, offering significant potential to enhance researchers' abilities to detect complex genetic changes in cancer genomes.... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.